Eli Lilly Eyes New Trials For Weight-Loss Drugs In Non-Obese Patients

Pharmaceutical giant Eli Lilly and Co (NYSE:LLY) is reportedly exploring broader applications for its popular weight-loss drugs, Mounjaro and Zepbound.

The company is considering clinical trials targeting individuals with a lower body mass index (BMI), expanding beyond the obese patient population to include those not classified as overweight but at risk of gaining weight.

In a Financial Times report, CEO Dave Ricks highlighted the company’s plans to study the effects of these medications on people with a BMI of 25, compared to the standard BMI threshold of 27 in Europe and the U.S. for ...